<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35495645</PMID><DateRevised><Year>2022</Year><Month>05</Month><Day>03</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1664-302X</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in microbiology</Title><ISOAbbreviation>Front Microbiol</ISOAbbreviation></Journal><ArticleTitle>Novel Antiviral Activity of Ethyl 3-Hydroxyhexanoate Against Coxsackievirus B Infection.</ArticleTitle><Pagination><StartPage>875485</StartPage><MedlinePgn>875485</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">875485</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fmicb.2022.875485</ELocationID><Abstract><AbstractText>Coxsackievirus group B (CVB) is a member of the genus <i>Enterovirus</i> in the family <i>Picornaviridae</i>. CVB infection has been implicated as a major etiologic agent of viral myocarditis, dilated cardiomyopathy, meningitis, and pancreatitis among children and young adults. Until date, no antiviral agent has been licensed for the treatment of Coxsackievirus infection. In an effort to identify antiviral agents against diseases caused by the CVB, we found that ethyl 3-hydroxyhexanoate (EHX), a volatile compound present in fruits and food additives, is a potent antiviral compound. In this study, we demonstrated that EHX treatment significantly inhibits CVB replication both <i>in vivo</i> and <i>in vitro</i>. Furthermore, EHX possesses antiviral activity at 50% effective concentration (EC<sub>50</sub>) of 1.2 &#x3bc;M and 50% cytotoxicity (CC<sub>50</sub>) of 25.6 &#x3bc;M, yielding a selective index (SI) value as high as 20.8. Insights into the mechanism of antiviral activity of EHX showed that it acts at the step of viral RNA replication. Since EHX has received approval as food additives, treatment of CVB-related infections with EHX might be a safe therapeutic option and may be a promising strategy for the development of semi-synthetic antiviral drugs for viral diseases.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Olasunkanmi, Mageto, Avala Ntsigouaye, Yi, Fei, Chen, Chen, Xu, Lin, Zhao, Wang and Zhong.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Olasunkanmi</LastName><ForeName>Oluwatayo Israel</ForeName><Initials>OI</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Harbin Medical University, Harbin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mageto</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Harbin Medical University, Harbin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Avala Ntsigouaye</LastName><ForeName>Juval</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Harbin Medical University, Harbin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yi</LastName><ForeName>Ming</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Harbin Medical University, Harbin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fei</LastName><ForeName>Yanru</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Harbin Medical University, Harbin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Harbin Medical University, Harbin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Sijia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Harbin Medical University, Harbin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Weizhen</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Harbin Medical University, Harbin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Lexun</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Harbin Medical University, Harbin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Wenran</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, Harbin Medical University, Harbin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, Harbin Medical University, Harbin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Zhao-Hua</ForeName><Initials>ZH</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Harbin Medical University, Harbin, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Microbiol</MedlineTA><NlmUniqueID>101548977</NlmUniqueID><ISSNLinking>1664-302X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coxsackievirus B</Keyword><Keyword MajorTopicYN="N">antiviral efficacy</Keyword><Keyword MajorTopicYN="N">ethyl 3-hydroxyhexanoate</Keyword><Keyword MajorTopicYN="N">natural product</Keyword><Keyword MajorTopicYN="N">viral diseases</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>2</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>2</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35495645</ArticleId><ArticleId IdType="pmc">PMC9048257</ArticleId><ArticleId IdType="doi">10.3389/fmicb.2022.875485</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Akram M., Tahir I. M., Shah S. M. A., Mahmood Z., Altaf A., Ahmad K., et al. (2018). Antiviral potential of medicinal plants against HIV, HSV, influenza, hepatitis, and coxsackievirus: a systematic review. Phytother. Res. 32 811&#x2013;822. 10.1002/ptr.6024</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ptr.6024</ArticleId><ArticleId IdType="pubmed">29356205</ArticleId></ArticleIdList></Reference><Reference><Citation>Bessaud M., Delpeyroux F. (2020). Enteroviruses-the famous unknowns. Lancet Infect. Dis. 20 268&#x2013;269. 10.1016/S1473-3099(19)30636-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(19)30636-X</ArticleId><ArticleId IdType="pubmed">31870906</ArticleId></ArticleIdList></Reference><Reference><Citation>Beutler J. A. (2009). Natural products as a foundation for drug discovery. Curr. Protoc. Pharmacol. 46 9.11.1&#x2013;9.11.21. 10.1002/0471141755.ph0911s46</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/0471141755.ph0911s46</ArticleId><ArticleId IdType="pmc">PMC2813068</ArticleId><ArticleId IdType="pubmed">20161632</ArticleId></ArticleIdList></Reference><Reference><Citation>Bracken M. B. (2009). Why animal studies are often poor predictors of human reactions to exposure. J. R. Soc. Med. 102 120&#x2013;122. 10.1258/jrsm.2008.08k033</Citation><ArticleIdList><ArticleId IdType="doi">10.1258/jrsm.2008.08k033</ArticleId><ArticleId IdType="pmc">PMC2746847</ArticleId><ArticleId IdType="pubmed">19297654</ArticleId></ArticleIdList></Reference><Reference><Citation>Burch G. E., Chu K. C., Soike K. F. (1982). Experimental coxsackievirus B4 valvulitis in squirrel monkeys. Exp. Mol. Pathol. 36 414&#x2013;422. 10.1016/0014-4800(82)90070-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0014-4800(82)90070-3</ArticleId><ArticleId IdType="pubmed">6282621</ArticleId></ArticleIdList></Reference><Reference><Citation>Burch G. E., Giles T. D., Colcolough H. L. (1970). Pathogenesis of &#x201c;rheumatic&#x201d; heart disease:critique and theory. Am. Heart J. 80 556&#x2013;561. 10.1016/0002-8703(70)90205-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0002-8703(70)90205-x</ArticleId><ArticleId IdType="pubmed">5471218</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Y. S., Williamson P. R., Zheng W. (2019). Improving therapy of severe infections through drug repurposing of synergistic combinations. Curr. Opin. Pharmacol. 48 92&#x2013;98. 10.1016/j.coph.2019.07.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coph.2019.07.006</ArticleId><ArticleId IdType="pmc">PMC6858965</ArticleId><ArticleId IdType="pubmed">31454708</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang L. C., Ng L. T., Cheng P. W., Chiang W., Lin C. C. (2005). Antiviral activities of extracts and selected pure constituents of Ocimum basilicum. Clin. Exp. Pharmacol. Physiol. 32 811&#x2013;816. 10.1111/j.1440-1681.2005.04270.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1681.2005.04270.x</ArticleId><ArticleId IdType="pubmed">16173941</ArticleId></ArticleIdList></Reference><Reference><Citation>Choy K. T., Wong A. Y., Kaewpreedee P., Sia S. F., Chen D., Hui K. P. Y., et al. (2020). Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res. 178 104786. 10.1016/j.antiviral.2020.104786</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2020.104786</ArticleId><ArticleId IdType="pmc">PMC7127386</ArticleId><ArticleId IdType="pubmed">32251767</ArticleId></ArticleIdList></Reference><Reference><Citation>Cragg G. M., Newman D. J., Snader K. M. (1997). Natural products in drug discovery and development. J. Nat. Prod. 60 52&#x2013;60. 10.1021/np9604893</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/np9604893</ArticleId><ArticleId IdType="pubmed">9014353</ArticleId></ArticleIdList></Reference><Reference><Citation>Du Y. X., Chen X. P. (2020). Response to &#x201c;dose rationale for favipiravir use in patients infected with SARS-CoV-2&#x201d;. Clin. Pharmacol. Ther. 108:190. 10.1002/cpt.1878</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.1878</ArticleId><ArticleId IdType="pmc">PMC7267349</ArticleId><ArticleId IdType="pubmed">32353191</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunkel M., Schmidt U., Struck S., Berger L., Gruening B., Hossbach J., et al. (2009). SuperScent&#x2013;a database of flavors and scents. Nucleic Acids Res. 37 D291&#x2013;D294. 10.1093/nar/gkn695</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkn695</ArticleId><ArticleId IdType="pmc">PMC2686498</ArticleId><ArticleId IdType="pubmed">18931377</ArticleId></ArticleIdList></Reference><Reference><Citation>Fechner H., Pinkert S., Geisler A., Poller W., Kurreck J. (2011). Pharmacological and biological antiviral therapeutics for cardiac coxsackievirus infections. Molecules 16 8475&#x2013;8503. 10.3390/molecules16108475</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules16108475</ArticleId><ArticleId IdType="pmc">PMC6264230</ArticleId><ArticleId IdType="pubmed">21989310</ArticleId></ArticleIdList></Reference><Reference><Citation>Fieldhouse J. K., Wang X., Mallinson K. A., Tsao R. W., Gray G. C. (2018). A systematic review of evidence that enteroviruses may be zoonotic. Emerg. Microbes Infect. 7:164. 10.1038/s41426-018-0159-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41426-018-0159-1</ArticleId><ArticleId IdType="pmc">PMC6158190</ArticleId><ArticleId IdType="pubmed">30258048</ArticleId></ArticleIdList></Reference><Reference><Citation>Food and Agriculture Organization of the United Nations [FAOUN] (2002). Specifications for Flavourings. Available online at: http://www.fao.org/food/food-safety-quality/scientific-advice/jecfa/jecfa-flav/details/en/c/1108/
(accessed 2002, October 15).</Citation></Reference><Reference><Citation>Furuta Y., Komeno T., Nakamura T. (2017). Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 93 449&#x2013;463. 10.2183/pjab.93.027</Citation><ArticleIdList><ArticleId IdType="doi">10.2183/pjab.93.027</ArticleId><ArticleId IdType="pmc">PMC5713175</ArticleId><ArticleId IdType="pubmed">28769016</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Q., Yuan S., Zhang C., Wang Y., Wang Y., He G., et al. (2015). Discovery of itraconazole with broad-spectrum in vitro antienterovirus activity that targets nonstructural protein 3A. Antimicrob. Agents Chemother. 59 2654&#x2013;2665. 10.1128/AAC.05108-14</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.05108-14</ArticleId><ArticleId IdType="pmc">PMC4394834</ArticleId><ArticleId IdType="pubmed">25691649</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg N., Sethupathy A., Tuwani R., Nk R., Dokania S., Iyer A., et al. (2018). FlavorDB: a database of flavor molecules. Nucleic Acids Res. 46 D1210&#x2013;D1216. 10.1093/nar/gkx957</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkx957</ArticleId><ArticleId IdType="pmc">PMC5753196</ArticleId><ArticleId IdType="pubmed">29059383</ArticleId></ArticleIdList></Reference><Reference><Citation>Gingold H., Pilpel Y. (2011). Determinants of translation efficiency and accuracy. Mol. Syst. Biol. 7:481. 10.1038/msb.2011.14</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/msb.2011.14</ArticleId><ArticleId IdType="pmc">PMC3101949</ArticleId><ArticleId IdType="pubmed">21487400</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Z., Zhang Y., Huang K., Wang J., Tian H., Song Y., et al. (2019). Two Coxsackievirus B3 outbreaks associated with hand, foot, and mouth disease in China and the evolutionary history worldwide. BMC Infect. Dis. 19:466. 10.1186/s12879-019-4107-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-019-4107-z</ArticleId><ArticleId IdType="pmc">PMC6534883</ArticleId><ArticleId IdType="pubmed">31126252</ArticleId></ArticleIdList></Reference><Reference><Citation>Honkimaa A., Kimura B., Sioofy-Khojine A. B., Lin J., Laiho J., Oikarinen S., et al. (2020). Genetic adaptation of coxsackievirus B1 during persistent infection in pancreatic cells. Microorganisms 8:1790. 10.3390/microorganisms8111790</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms8111790</ArticleId><ArticleId IdType="pmc">PMC7697981</ArticleId><ArticleId IdType="pubmed">33203081</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang B., Harrower B., Burtonclay P., Constantino T., Warrilow D. (2017). Genome sequences of Coxsackievirus B5 isolates from two children with meningitis in Australia. Genome Announc 5 e1125&#x2013;e1117. 10.1128/genomeA.01125-17</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/genomeA.01125-17</ArticleId><ArticleId IdType="pmc">PMC5637508</ArticleId><ArticleId IdType="pubmed">29025948</ArticleId></ArticleIdList></Reference><Reference><Citation>Huber S. A. (2008). Coxsackievirus B3-induced myocarditis: infection of females during the estrus phase of the ovarian cycle leads to activation of T regulatory cells. Virology 378 292&#x2013;298. 10.1016/j.virol.2008.05.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2008.05.015</ArticleId><ArticleId IdType="pmc">PMC2596296</ArticleId><ArticleId IdType="pubmed">18586295</ArticleId></ArticleIdList></Reference><Reference><Citation>Joshi S., Parkar J., Ansari A., Vora A., Talwar D., Tiwaskar M., et al. (2021). Role of favipiravir in the treatment of COVID-19. Int. J. Infect. Dis. 102 501&#x2013;508. 10.1016/j.ijid.2020.10.069</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.10.069</ArticleId><ArticleId IdType="pmc">PMC7831863</ArticleId><ArticleId IdType="pubmed">33130203</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitchen D. B., Decornez H., Furr J. R., Bajorath J. (2004). Docking and scoring in virtual screening for drug discovery: methods and applications. Nat. Rev. Drug. Discov. 3 935&#x2013;949. 10.1038/nrd1549</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd1549</ArticleId><ArticleId IdType="pubmed">15520816</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis W., Dalakas M. C. (1995). Mitochondrial toxicity of antiviral drugs. Nat. Med. 1 417&#x2013;422. 10.1038/nm0595-417</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm0595-417</ArticleId><ArticleId IdType="pubmed">7585087</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Wang M., Cheng A., Wen X., Ou X., Mao S., et al. (2020). Enterovirus replication organelles and inhibitors of their formation. Front. Microbiol. 11:1817. 10.3389/fmicb.2020.01817</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2020.01817</ArticleId><ArticleId IdType="pmc">PMC7468505</ArticleId><ArticleId IdType="pubmed">32973693</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin L. T., Hsu W. C., Lin C. C. (2014). Antiviral natural products and herbal medicines. J. Tradit. Complement Med. 4 24&#x2013;35. 10.4103/2225-4110.124335</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/2225-4110.124335</ArticleId><ArticleId IdType="pmc">PMC4032839</ArticleId><ArticleId IdType="pubmed">24872930</ArticleId></ArticleIdList></Reference><Reference><Citation>Lugo D., Krogstad P. (2016). Enteroviruses in the early 21st century: new manifestations and challenges. Curr. Opin. Pediatr. 28 107&#x2013;113. 10.1097/MOP.0000000000000303</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MOP.0000000000000303</ArticleId><ArticleId IdType="pmc">PMC4750492</ArticleId><ArticleId IdType="pubmed">26709690</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukashev A. N., Vakulenko Y. A. (2017). Molecular evolution of types in non-polio enteroviruses. J. Gen. Virol. 98 2968&#x2013;2981. 10.1099/jgv.0.000966</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jgv.0.000966</ArticleId><ArticleId IdType="pubmed">29095688</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahavy C. E., Duez P., ElJaziri M., Rasamiravaka T. (2020). African plant-based natural products with antivirulence activities to the rescue of antibiotics. Antibiotics (Basel) 9:830. 10.3390/antibiotics9110830</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics9110830</ArticleId><ArticleId IdType="pmc">PMC7699609</ArticleId><ArticleId IdType="pubmed">33228261</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q., Wang Y., Yao X., Bian L., Wu X., Xu M., et al. (2014). Coxsackievirus A16: epidemiology, diagnosis, and vaccine. Hum. Vaccin Immunother. 10 360&#x2013;367. 10.4161/hv.27087</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.27087</ArticleId><ArticleId IdType="pmc">PMC4185891</ArticleId><ArticleId IdType="pubmed">24231751</ArticleId></ArticleIdList></Reference><Reference><Citation>Medina S., Perestrelo R., Pereira R., Camara J. S. (2020). Evaluation of volatilomic fingerprint from apple fruits to ciders: a useful tool to find putative biomarkers for each apple variety. Foods 9:1830. 10.3390/foods9121830</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/foods9121830</ArticleId><ArticleId IdType="pmc">PMC7763333</ArticleId><ArticleId IdType="pubmed">33317039</ArticleId></ArticleIdList></Reference><Reference><Citation>Oikawa P. Y., Lerdau M. T. (2013). Catabolism of volatile organic compounds influences plant survival. Trends Plant Sci. 18 695&#x2013;703. 10.1016/j.tplants.2013.08.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tplants.2013.08.011</ArticleId><ArticleId IdType="pubmed">24060580</ArticleId></ArticleIdList></Reference><Reference><Citation>Olasunkanmi O. I., Chen S., Mageto J., Zhong Z. (2020). Virus-induced cytoplasmic aggregates and inclusions are critical cellular regulatory and antiviral factors. Viruses 12:399. 10.3390/v12040399</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v12040399</ArticleId><ArticleId IdType="pmc">PMC7232513</ArticleId><ArticleId IdType="pubmed">32260341</ArticleId></ArticleIdList></Reference><Reference><Citation>Pham J. V., Yilma M. A., Feliz A., Majid M. T., Maffetone N., Walker J. R., et al. (2019). A review of the microbial production of bioactive natural products and biologics. Front. Microbiol. 10:1404. 10.3389/fmicb.2019.01404</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2019.01404</ArticleId><ArticleId IdType="pmc">PMC6596283</ArticleId><ArticleId IdType="pubmed">31281299</ArticleId></ArticleIdList></Reference><Reference><Citation>Prempeh H., Smith R., Muller B. (2001). Foot and mouth disease: the human consequences. The health consequences are slight, the economic ones huge. BMJ 322 565&#x2013;566. 10.1136/bmj.322.7286.565</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.322.7286.565</ArticleId><ArticleId IdType="pmc">PMC1119772</ArticleId><ArticleId IdType="pubmed">11238137</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos D. A., Shi L., Tu B. P., Weissman J. S. (2019). Cycloheximide can distort measurements of mRNA levels and translation efficiency. Nucleic Acids Res. 47 4974&#x2013;4985. 10.1093/nar/gkz205</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkz205</ArticleId><ArticleId IdType="pmc">PMC6547433</ArticleId><ArticleId IdType="pubmed">30916348</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider-Poetsch T., Ju J., Eyler D. E., Dang Y., Bhat S., Merrick W. C., et al. (2010). Inhibition of eukaryotic translation elongation by cycloheximide and lactimidomycin. Nat. Chem. Biol. 6 209&#x2013;217. 10.1038/nchembio.304</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nchembio.304</ArticleId><ArticleId IdType="pmc">PMC2831214</ArticleId><ArticleId IdType="pubmed">20118940</ArticleId></ArticleIdList></Reference><Reference><Citation>Souii A., Ben M&#x2019;hadheb-Gharbi M., Gharbi J. (2013). Role of RNA structure motifs in IRES-dependent translation initiation of the coxsackievirus B3: new insights for developing live-attenuated strains for vaccines and gene therapy. Mol. Biotechnol. 55 179&#x2013;202. 10.1007/s12033-013-9674-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12033-013-9674-4</ArticleId><ArticleId IdType="pubmed">23881360</ArticleId></ArticleIdList></Reference><Reference><Citation>Strasfeld L., Chou S. (2010). Antiviral drug resistance: mechanisms and clinical implications. Infect. Dis. Clin. North Am. 24 413&#x2013;437. 10.1016/j.idc.2010.01.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idc.2010.01.001</ArticleId><ArticleId IdType="pmc">PMC2871161</ArticleId><ArticleId IdType="pubmed">20466277</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L., Meijer A., Froeyen M., Zhang L., Thibaut H. J., Baggen J., et al. (2015). Antiviral activity of broad-spectrum and enterovirus-specific inhibitors against clinical isolates of enterovirus D68. Antimicrob. Agents Chemother. 59 7782&#x2013;7785. 10.1128/AAC.01375-15</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01375-15</ArticleId><ArticleId IdType="pmc">PMC4649165</ArticleId><ArticleId IdType="pubmed">26369972</ArticleId></ArticleIdList></Reference><Reference><Citation>Thibaut H. J., De Palma A. M., Neyts J. (2012). Combating enterovirus replication: state-of-the-art on antiviral research. Biochem. Pharmacol. 83 185&#x2013;192. 10.1016/j.bcp.2011.08.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2011.08.016</ArticleId><ArticleId IdType="pubmed">21889497</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian L., Yang Y., Li C., Chen J., Li Z., Li X., et al. (2018). The cytotoxicity of coxsackievirus B3 is associated with a blockage of autophagic flux mediated by reduced syntaxin 17 expression. Cell Death Dis. 9:242. 10.1038/s41419-018-0271-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-018-0271-0</ArticleId><ArticleId IdType="pmc">PMC5833838</ArticleId><ArticleId IdType="pubmed">29445155</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsueng G., Tabor-Godwin J. M., Gopal A., Ruller C. M., Deline S., An N., et al. (2011). Coxsackievirus preferentially replicates and induces cytopathic effects in undifferentiated neural progenitor cells. J. Virol. 85 5718&#x2013;5732. 10.1128/JVI.02261-10</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02261-10</ArticleId><ArticleId IdType="pmc">PMC3126326</ArticleId><ArticleId IdType="pubmed">21471247</ArticleId></ArticleIdList></Reference><Reference><Citation>Tungmunnithum D., Thongboonyou A., Pholboon A., Yangsabai A. (2018). Flavonoids and other phenolic compounds from medicinal plants for pharmaceutical and medical aspects: an overview. Medicines (Basel) 5:93. 10.3390/medicines5030093</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicines5030093</ArticleId><ArticleId IdType="pmc">PMC6165118</ArticleId><ArticleId IdType="pubmed">30149600</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuthill T. J., Groppelli E., Hogle J. M., Rowlands D. J. (2010). Picornaviruses. Curr. Top. Microbiol. Immunol. 343 43&#x2013;89. 10.1007/82_2010_37</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/82_2010_37</ArticleId><ArticleId IdType="pmc">PMC3018333</ArticleId><ArticleId IdType="pubmed">20397067</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Linden L., Wolthers K. C., van Kuppeveld F. J. (2015). Replication and inhibitors of enteroviruses and parechoviruses. Viruses 7 4529&#x2013;4562. 10.3390/v7082832</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v7082832</ArticleId><ArticleId IdType="pmc">PMC4576193</ArticleId><ArticleId IdType="pubmed">26266417</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Li G., Yuan S., Gao Q., Lan K., Altmeyer R., et al. (2016). In vitro assessment of combinations of enterovirus inhibitors against enterovirus 71. Antimicrob. Agents Chemother. 60 5357&#x2013;5367. 10.1128/AAC.01073-16</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01073-16</ArticleId><ArticleId IdType="pmc">PMC4997834</ArticleId><ArticleId IdType="pubmed">27353263</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Zhao S., Chen Y., Wang Y., Wang T., Wo X., et al. (2020). N-Acetyl cysteine effectively alleviates Coxsackievirus B-Induced myocarditis through suppressing viral replication and inflammatory response. Antiviral Res. 179:104699. 10.1016/j.antiviral.2019.104699</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2019.104699</ArticleId><ArticleId IdType="pubmed">31883926</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo J., Quinn K. K., Kye S., Cooper P., Damoiseaux R., Krogstad P. (2012). Fluoxetine is a potent inhibitor of coxsackievirus replication. Antimicrob. Agents Chemother. 56 4838&#x2013;4844. 10.1128/AAC.00983-12</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00983-12</ArticleId><ArticleId IdType="pmc">PMC3421851</ArticleId><ArticleId IdType="pubmed">22751539</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>